Background: Buckwheat (Fagopyrum esculentum) has become increasingly popular as a healthy food in Europe. However, for sensitized individuals, consumption can cause anaphylactic reactions. The aim of this study was to identify individual wellcharacterized buckwheat allergens for component-resolved diagnosis.
| INTRODUCTION
In Asian countries, common buckwheat (Fagopyrum esculentum) is a popular, traditional food. Nowadays, it becomes increasingly popular also in Western countries as part of a healthy diet 1 due to its wellbalanced amino acid composition. 2 Buckwheat is also used as a substitute in gluten-free food, especially for people suffering from coeliac disease.
Although the prevalence of buckwheat allergy is relatively low (0.22% in Japan, 0.11% in Korea), 3, 4 it is often associated with severe anaphylaxis. Similar to peanut allergy, even small amounts can cause severe, life-threatening reactions. 5 This is an important issue because buckwheat is often consumed as a hidden allergen in cakes, pancakes, and pastries. In Japan, it is estimated that 2.9%-3.4% of all reported anaphylactic events to foods are caused by buckwheat, 6 while in Korea, buckwheat has been identified as the leading cause of food allergy. 7 In
Europe, data concerning the prevalence of buckwheat allergy are limited to date. Two Italian studies reported a sensitization prevalence of 3.6% and a prevalence of buckwheat anaphylaxis of 1%, respectively.
In France, the prevalence was 4.5% of cases of food anaphylaxis. [8] [9] [10] Currently, the widely used first-line diagnostic approach of buckwheat allergy is skin prick test (SPT) and in vitro tests such as ImmunoCAP, to detect and quantify buckwheat-specific IgE (sIgE).
However, despite high sensitivity, the specificity of these tests are low. 11 Thus, in many cases, food challenges are still the gold standard for a proper diagnosis.
Component-resolved diagnosis (CRD) allows to discriminate
between clinically relevant and non-relevant sensitization for many food allergen sources (e.g. peanut, hazelnut, kiwifruit). 12 Although buckwheat is recognized as a major food allergen source, there is limited knowledge on the causative allergens. Up to now, three important buckwheat allergens have been identified, named Fag e 1-3. Urisu et al. 13 characterized a protein of approximately 24 kDa with high IgE-binding potential that was identified as the small subunit of buckwheat legumin (13S globulin) and tentatively designated Fag e 1.
14 Predominantly severe reactions are observed in patients sensitized to a 16 kDa protein that was identified as a member of the 2S albumin family. 15, 16 19, 20 This study aimed to identify individual buckwheat allergens including potential marker allergens for CRD. Therefore, we evaluated and compared the allergen recognition pattern in sera from patients allergic to buckwheat and patients sensitized, but tolerant to ingestion of buckwheat, respectively. We further assessed the allergenic potential of the purified individual proteins including legumin, vicilin, and 2S albumin. Sera from sensitized individuals, allergic patients, and non-allergic control subjects diluted 1:10 were applied onto the plates overnight at 4°C. Bound IgE was detected by incubation with a 1:1000 diluted alkaline phosphatase-conjugated mouse anti-human IgE antibody (BD BioSciences, Heidelberg, Germany) for 2 hours at room temperature, and colour development was performed using disodium pnitrophenyl phosphate substrate tablets. OD was measured at 405 nm, and the mean value of the negative controls (healthy donors) plus 39 SD was used as the threshold. All sera were tested in duplicates.
| Statistics
Results are given as medians and ranges. Statistical analyses were performed using the Mann-Whitney test for differences between independent samples and Chi square for differences between groups. P-values below .05 were considered significant. Analyses were performed with GraphPad Prism (GraphPad Software, La Jolla, USA) and STATA12 SE (Stata Corporation, College Station, TX, USA).
3 | RESULTS
| Clinical data
Fifty-two patients, 34 female and 18 male (median age 41, range 6-71 years), with a positive SPT for buckwheat were included in this study. The patients were divided into two subgroups ( Figure S1) ; the allergic group included 11 patients, diagnosed with buckwheat allergy (median age 52, range 34-67 years), and the sensitized group included 41 subjects who were sensitized without clinical symptoms upon oral intake of buckwheat (median age 33, range 6-71 years). All buckwheat-allergic patients had experienced a severe allergic reaction to food containing buckwheat such a pancakes, blinis, or cake. According to Sampson's severity score, 21 all patients in this study reacted with anaphylaxis grade 2-5 (Table S1 ). Among patients from the buckwheat-allergic group, eight patients were tested for buckwheat-sIgE and all were positive. From the SPT-sensitized subgroup, 18 were tested for buckwheat-sIgE and ten were positive (55.5%). Of the 10 in the sensitized subgroup, five had a negative food challenge, one patient had consumed buckwheat at home but without symptoms, and four had no clinical suspicion of buckwheat allergy ( Figure S1 ).
Median sIgE for SPT-sensitized and allergic patients was 0.65 kU A / L (range: <0.35-14.2 kU A /L) and 4.7 kU A /L (range: 1.9-36.9 kU A /L),
respectively. There was a significant difference between the groups (P < .002). Buckwheat-allergic patients had a significantly larger median SPT weal diameter for buckwheat than the sensitized group (P < .0001) (median: 10.0 mm vs 4.5 mm). The median weal diameter in allergic individuals was significantly larger than the diameter of the positive control (P < .0003) (median: 10.0 mm vs 6.0 mm), whereas the median diameter of the sensitized group was significantly smaller than that of the controls (P < .0001) (median:
4.5 mm vs 6.5 mm). Data are summarized in Table 1 .
Cosensitizations to pollen, foods, and latex were tested by SPT (Table S2 ). Among the buckwheat-sensitized, 80% were sensitized to one or more pollen compared to 50% in the buckwheat-allergic group (P = .05). In the sensitized group, 20% reacted to all 3 pollen compared to 0% in the buckwheat-allergic group. Buckwheat-sensitized patients were sensitized to hazelnut (70%), cereal grains (71%), wheat (68%), sesame (53%), soy (46%), poppy seed (42%), peanut (38%), and latex (12.5%). In contrast, none of the buckwheat-allergic patients were sensitized to foods or latex. Table S3 summarizes IgE cosensitizations among buckwheat-allergic and buckwheat-sensitized patients. All buckwheat-sensitized patients positive for sIgE were tested positive for peanut-specific IgE.
Of these, two were diagnosed with peanut allergy also having the highest buckwheat-specific IgE in the buckwheat-sensitized group, 14.2 and 6 kUA/L, respectively. Nine of 10 and 6 of 9 buckwheat-sensitized IgE positive patients were also cosensitized to grass pollen and birch pollen, respectively. Four of 11 and 0 of 10 allergic patients were cosensitized to grass pollen and birch pollen, respectively (Table S3) .
To obtain a better overview of cosensitization patterns of the two groups, we analyzed 34 of the buckwheat samples (27 sensitized and 7 allergic), where serum was available, using ImmunoCAP ISAC. However, the only buckwheat component on the ISAC was Fag e 2. The analysis revealed that only three of seven buckwheatallergic patients' sera and 1 of 27 of sensitized displayed Fag e 2-specific IgE (A3, A4, and A11). Interestingly, these sera were tested negative for all other components (112 in total). Four of seven (A1, A6, A7, and A9) did not show any positive reaction on the chip. In the buckwheat-sensitized group, 10 of 27 did not recognize any allergen. The results are summarized in Table S4 .
| IgE immunoblotting with buckwheat extract clearly shows a distinct pattern in allergic patients
IgE allergen recognition patterns were analysed using sera from 27 sensitized and 7 allergic patients (Figure 1) . At non-reducing GEISELHART ET AL. 
| Purification and identification of several important buckwheat allergens
To identify and characterize the IgE-binding proteins, we purified the components using a combination of precipitation and chromatographic methods. The purified proteins were identified by N-terminal sequencing and/or tandem mass spectrometry or confirmed by MALDI-TOF mass spectrometry (Figure S3A-D) . Figure 2 shows all purified components at reducing and non-reducing conditions. The most abundant component was legumin (L-S, disulphide-linked small and large subunit; 55-70 kDa), which after reduction was separated into a small (S;
Fag e 1; 18-22 kDa) and a large subunit (L; 33-38 kDa), providing the typical pattern of legumins. 22 Immunoblots using purified legumin were performed at non-reducing and reducing conditions ( Figure S4 ).
Binding of sIgE to the native protein (L-S) was observed when testing sera from buckwheat-allergic patients (5 of 7 sera). However, upon reduction, only 2 of 7 sera recognized the small subunit ( Figure S4 ). In addition, sera from 2 healthy donors as well as 3 from sensitized individuals also displayed IgE binding to the small subunit.
An additional purified protein separated into two major bands of about 55 kDa and~35 kDa exhibiting only small changes in mobility after reduction. Mass spectrometric analysis identified it as a member of the vicilin family of allergens (7S globulin) and has been designated 55-70 kDa). Interestingly, four of the sensitized group showed extremely high IgE levels, even higher than sera from the allergic group.
All sera from buckwheat-allergic patients displayed anti-Fag e 2-specific IgE. Within the sensitized group, only 4 of 27 had Fag e 2-sIgE.
Six of 7 allergic patients' sera showed a strong reaction to Fag e 5.
The newly identified allergen Fag e 4 was recognized by 5 of 7 sera from buckwheat-allergic patients. Figure 4 gives an overview on the individual IgE reactivity profiles of patients with buckwheat allergy and patients sensitized to buckwheat.
Finally, the sensitivities and specificities of ImmunoCAP, ISAC, and ELISA-tests were calculated and are shown in Table 2 . Although
ImmunoCAP analysis showed a sensitivity of 100%, the specificity was rather low (44%). Fag e 2 on the ISAC chip had a sensitivity of only 43% and a specificity of 96%. Analysis performed for the different components, namely legumin, Fag e 2, Fag e 4, and Fag e 5, revealed sensitivities of 100%, 100%, 71%, and 86%, and specificities of 67%, 85%, 81%, and 74%, respectively.
| DISCUSSION
In this study, we examined the allergen recognition patterns in a We showed that full-length buckwheat legumin (L-S; 55-70 kDa) from the seed storage protein family did not only provide a strong signal on the immunoblot, but also bound significantly more sIgE in sera from allergic patients as compared to the control group. Previous reports described the small subunit of the legumin (BW24KD) 13 as a major allergen, also designated Fag e 1. 14 In our study, fulllength legumin (L-S; 55-70 kDa) was recognized by 5 of 7 sera.
However, upon reduction, only 2 of 7 sera from allergic patients reacted with the small subunit (S; 18-22 kDa; Fag e 1) but also sera from the control group as well as from healthy donors ( Figure S4 ).
This raises the question, whether the full-length protein providing access to all relevant IgE epitopes instead of the small subunit only is useful to clearly identify buckwheat-allergic patients. Our findings are in agreement with a previous study from Tohgi et al. who compared the reactivity of recombinant Fag e 1 and the purified native legumin. They could discriminate between sensitized but tolerant and allergic patients only by the application of native legumin. 25 Therefore, we suggest a re-evaluation whether the full-length legumin (L-S; 55-70 kDa) should be designated Fag e 1. Convincing data that the full-length buckwheat legumin is an important allergen also emerged from a mouse study, where sensitization of mice with recombinant full-length legumin resulted in increased expression of Th2 cytokines. Allergic group Serum A1 Serum A3 Serum A4 Serum A6 Serum A7 Serum A9 Serum A11 Sensitized group Serum S1 Serum S2 Serum S3 Serum S4 Serum S5 Serum S6 Serum S7 Serum S8 Serum S9 Serum S10 Serum S11 Serum S12 Serum S13 Serum S14 Serum S15 Serum S16 Serum S17 Serum S18 Serum S19 Serum S20 Serum S21 Serum S22 Serum S23 Serum S24 Serum S25 Serum S26 Serum S27
F I G U R E 4 IgE reactivity profiles to buckwheat extract and individual allergens in buckwheat-allergic and buckwheat-sensitized patients Another protein that turned out to be IgE-reactive discriminating between sensitized and allergic patients was identified as AMP1/2, antimicrobial peptides belonging to the hevein family. 23 This newly identified buckwheat allergen was registered in the allergen database (www.allergen.org) and designated Fag e 4. Sequence analysis revealed 65% sequence identity to hevein, a major allergen from Hevea brasiliensis. Fag e 4 may be the cross-reactive allergen that accounts for allergic reaction in patients sensitized to latex upon buckwheat consumption. 28 Despite a low prevalence of buckwheat allergy, it is one of the major foods causing severe life-threatening reactions. [3] [4] [5] [6] [7] 9 As neither skin testing nor the presence of buckwheat-sIgE proved to be useful for precisely predicting clinical allergy, the diagnosis is still based on a positive food challenge and/or a clear-cut history of severe reactions. Interestingly, we found that all patients with buckwheat allergy had a significantly larger SPT weal diameter to buckwheat compared to the positive control, whereas the buckwheat-sensitized had a significantly smaller SPT weal diameter to buckwheat compared to the positive control. Furthermore, the patient cohort showed that pollen cosensitizations were more common in patients asymptomatically sensitized to buckwheat compared to patients with buckwheat allergy. So far we could not identify a potential candidate for pollen cross-reaction to buckwheat. The vast majority of patients with buckwheat allergy had no or very few cosensitizations to foods or latex. In contrast, patients asymptomatically sensitized to buckwheat were sensitized to a range of other allergens. This is an interesting finding suggesting that cosensitizations without clinical buckwheat allergy might be primarily induced by other food sources such as peanut, sesame, or hazelnut. In contrast in the allergic group, buckwheat was the sensitizer, and cosensitizations to other food sources were virtually absent. To confirm our findings, it would be interesting to test a larger cohort of buckwheat-allergic patients as well as patients allergic to other food sources from different regions all over Europe.
Precise in vitro diagnosis of buckwheat allergy as well as a potential prediction of the severity of symptoms is highly needed. 
ACKNOWLEDG EMENT
This work was supported by grant SFB F4603 and W1248 from the Austrian Science Fund.
CONFLI CT OF INTEREST
The authors declare that they have no conflicts of interest. 
